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Abstract
Antitumor activity of the adduct between Carboplatin and (z-cyclodextrin has been tested against
Sarcoma 180 ($18o) and Ehrlich ascites carcinoma (EAC) murine tumors. The preliminary toxicity has
also been evaluated by histological examinations of the treated animals. The results show the
adduct has less antitumor efficacy than and similar toxicity to Carboplatin.
1. Introduction
Carboplatin,diammine [1,1-cyclobutanedicarboxylato]platinum(ll), is a well known antitumor
platinum drug. At present, it is provided in the form of a lyophilised powder which has to be
reconstituted into an injectable solution form just before administration. Unfortunately the resulting
solution is stable for only 8 hours at room temperature[I]. After this period, it is recommended that
the solution should be discarded. Consequently the methods for improving the aqueous stability
of Carboplatin merit consideration. It has been reported that Carboplatin can be included into
cyclodextrin as a 1:1 adduct [2][3] and that the inclusion markly increases aqueous stability of
Carboplatin [4]. Whether the inclusion affects its antitumor activity remained an open question. In
order to further evaluate the possibility of using clinically this adduct, we have studied the
influence of inclusion on the antitumor activity and preliminary toxicity of Carboplatin, and report our
results here.
2. Experimental part
The adduct of Carboplatin into o-cyclodextrin was synthesized and purified according to a reported
method [4]. Its molecular formula was determined by elemental analysis and MS-FAB to be
[(NH3)2Pt(C6H604).(C6H1005).8H20] (experimental values: Pt 13.1 5%, C 34.07%, N 1.84%, H
5.95%, MS-FAB+ m/e 1489 (M+I); calculated values: Pt 13.10%, C 33.90%, N 1.88%, H 5.92%,
molecular weight 1488), the content of Carboplatin being 25% in the adduct. Female KM mice
weighing 18-20 grams, and two murine tumor models S80 and EAC were used in the experiments.
The adduct and free Carboplatin were dissolved immediately before use in sterile 5% glucose.
Mice bearing tumors were randomized into drug groups and control group. Each group had 15
mice. The control group was treated with the drug vehicle by the same route as drug groups. $180
cells were transplanted to 45 mice by injection into the left axillary site. 2 days later,the drugs were
administrated ip for 8 days and then tumors were dissected out and accurately weighed. The
weights of drug and control groups were compared. Liver, spleen, kidney and lung of the mice
were sumitted for histological examinations. Mice were transplanted ip with EAC cells, and 2 days
later administrated iv with the drugs for 6 days. Within a 60 day experiment,the survival were
recorded and activity of the drugs was assessed as the increase in life span. The tissues of the
mice surviving for 28-30 days were also taken out for histological examinations.
3. Results and disscussion
The antitumor activity of the adduct and of Carboplatin in the corresponding two murine tumor
models is listed in Table from which it can be seen that, although the adduct exhibits
considerable antitumor efficacy, it is obvisiously less effective than Carboplatin at equivalent doses.
This means that the inclusion of o-cyclodextrin reduces antitumor activity of Carboplatin. No
differences among the adduct and Carboplatin in pathological changes were observed, so the
toxicity of the adduct is probably comparable to that of Carboplatin. The reason for the decrease in
antitumor efficacy of the adduct is not yet understood but may be related to the difficulty in cellular
uptake due to the larger size of the adduct and/or to the dissociation equilibrium between included
and free Carboplatin, Carboplatin being only partly released from the adduct. The adduct shows no
superiority over Carboplatin in activity and toxicity except its aqueous stability. Therefore there
remains doubt of possible clinical uses of the adduct.
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Table 1. Antitumor activity of Adduct and Carboplatin against S8o and EAC murine tumors
Drug Tumor Schedule
Dose T/C%
(mg/kg) Tumor Weight Life Span
Carboplatin S180 ip daily x 8 30
15
Adduct S18O ip daily x 8 120 (30)*
60 (15)*
Carboplatin EAC iv daily x 6 5
Adduct EAC iv daily x 6 80 (20)*
60 (15)*
40 (10)*
70.7%
58.5%
53.7%
30.1%
168%
153%
131%
123%
Figures in brackets give the amount of Carboplatin in the adduct
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